Research use only, not for human consumption. Email [email protected]
← Research status explorer
Peak / Growth axis

CJC-1295

Current research status Human Research
Early/historical clinical research
Preclinical
Human Research

Overview

CJC-1295 is a modified GHRH analogue studied in early-phase human pharmacology trials evaluating its ability to raise growth hormone and IGF-1 levels. It has been administered to humans in published research, but has not been advanced through a conventional sponsor-run Phase 1–3 program to an approved product.

Last reviewed: September 2026